⚠ Backlog Is Not Revenue; Financing Is Not FreeModerate threat

The $20 billion backlog and the Brookfield financing are genuine strengths, but each carries caveats that temper the reassurance. The filings show the gap: $494 million of unsatisfied performance obligations at June 2026 against a backlog reported at around $20 billion,¹ a gap a July 2026 short-seller report made its central charge.² A backlog is a book of orders, not recognized revenue, and certainly not profit: it must be executed — systems built, shipped, installed, and serviced — over years, and along the way it carries risks of delay, cost overrun, cancellation, and thinner-than-expected margins. A large headline backlog number says demand is strong, which is real and valuable, but it says little with certainty about the profits Bloom will ultimately earn from it, especially if input costs rise, execution stumbles at the current unprecedented scale, or customers renegotiate as the market shifts. Backlog is a promise, and promises in a fast-moving, capital-intensive business are not the same as banked returns.

The reliance on external financing is likewise double-edged. Bloom's systems are expensive, and funding their deployment through partners like Brookfield enables growth Bloom could not self-finance — but it introduces cost (the financier expects a return), counterparty dependence (the growth relies on the partner continuing to fund), and sensitivity to financial conditions (terms can tighten, or capital grow scarcer, if sentiment toward the sector or the AI build-out sours). A business whose growth depends on continuous access to large external financing is more fragile in a downturn than one that funds itself. Neither caveat negates the strengths: a $20 billion backlog and a $25 billion financing commitment are powerful evidence of real, funded, multi-year demand, and they meaningfully distinguish Bloom from a pure momentum story. But an investor should hold them at their true worth — strong contracted demand and the means to serve it, subject to execution and financing risks — rather than as the certainty of profitable growth that the valuation — ~26x sales against ~34% gross margins³ — appears to assume in pricing the backlog as if already delivered.